Drug news
Exparel is FDA approved for Post Surgical Analgesia
Exparel(bupivacaine extended-release liposome injection),a non-opioid local analgesic, is FDA approved for post-surgical analgesia. Exparel provides analgesia for several days with a single intraoperative infiltration. The approval is based on a trial that showed a larger percentage of patients treated with Exparel avoided opioid rescue medication during the first 24 hours after surgery compared to placebo,,7% versus 1%. Exparel combines bupivacaine with DepoFoam drug delivery technology from Pacira Pharma.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins